Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6469137 | 0.85 | HSD11B1 (0.37) | HSD11B1PTPN1HDAC8HSD17B10UCHL1 | |
| SCHEMBL6466435 | 0.84 | OPRK1 (0.35) | OPRK1ALDH1A1PTPN1HDAC8HSD17B10 | |
| SCHEMBL6474046 | 0.83 | OPRK1 (0.37) | HSD11B1OPRK1ALDH1A1HDAC8ESR2 | |
| SCHEMBL6471376 | 0.79 | HSD11B1 (0.44) | HSD11B1PTPN1HDAC8UCHL1 | |
| SCHEMBL15893740 | 0.78 | ESR2 (0.46) | ESR2MEN1KMT2A | |
| SCHEMBL2732465 | 0.76 | POLB (0.43) | ALDH1A1PTPN1HDAC8MEN1KMT2A | |
| SCHEMBL2081158 | 0.74 | PTPN1 (0.47) | PTPN1HDAC8UCHL1 | |
| SCHEMBL16518049 | 0.73 | ESR2 (0.54) | ESR2MEN1KMT2A | |
| SCHEMBL7220966 | 0.73 | PTPN1 (0.48) | PTPN1HDAC8MEN1KMT2A | |
| SCHEMBL7220969 | 0.73 | PTPN1 (0.48) | PTPN1HDAC8MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | ITO FUMITAKA (JP) | 2005-07-14 | — | — | US | disclosed |
| US-20050113346-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH HOLDINGS CORPORATION | 2005-05-26 | — | — | US | disclosed |
| WO-2005016913-A1 | TETRAHYDROISOQUINOLINE OR ISOCHROMAN COMPOUNDS AS ORL-1 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN AND CNS DISORDERS | PFIZER JAPAN, INC. (JP) | 2005-02-24 | — | — | WO | disclosed |
| US-6812227-B2 | SULFUR COMPOUNDS SUCH AS 2-((4-BUT-2-YNYLOXY-BENZENESULFONYL)-METHYL-AMINO)-N-HYDROXY-3-METHYL -BUTYRAMIDE, USED AS TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME (TACE) INHIBITORS, FOR PROPHYLAXIS OF RHEUMATIC DISEASES, SEPSIS OR INFLAMMATION | WYETH HOLDINGS CORPORATION | 2004-11-02 | — | — | US | disclosed |
| US-6716833-B2 | RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, SEPSIS, AIDS, ULCERATIVE COLITIS, MULTIPLE SCLEROSIS, CROHN'S DISEASE AND DEGENERATIVE CARTILAGE LOSS. | WYETH HOLDINGS CORPORATION | 2004-04-06 | — | — | US | disclosed |
| US-20040033988-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH (US) | 2004-02-19 | — | — | US | disclosed |
| US-20030212049-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH (US) | 2003-11-13 | — | — | US | disclosed |
| US-20030008849-A1 | Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors | LEVIN JEREMY I (US) | 2003-01-09 | — | — | US | disclosed |
| US-6225311-B1 | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors | AMERICAN CYANAMID COMPANY | 2001-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008849-A1 | Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | HSD11B1 993/4885OPRK1 1846/4885ALDH1A1 716/4885 |
| US-20040033988-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | HSD11B1 993/4885OPRK1 1846/4885ALDH1A1 716/4885 |
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | OPRL1, NR1H3, HRH3 | HSD11B1 479/4885OPRK1 10/4885ALDH1A1 1598/4885 |
| US-20030212049-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | HSD11B1 993/4885OPRK1 1846/4885ALDH1A1 716/4885 |
| US-20050113346-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, MMP12 | HSD11B1 1418/4885OPRK1 1903/4885ALDH1A1 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.